<DOC>
	<DOCNO>NCT00066612</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy irinotecan use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness irinotecan treating patient recurrent refractory advance transitional cell cancer urothelium .</brief_summary>
	<brief_title>S0306 , Irinotecan Treating Patients With Recurrent Refractory Advanced Transitional Cell Cancer Urothelium Previously Treated With Chemotherapy</brief_title>
	<detailed_description>OBJECTIVES : - Determine probability response ( confirmed complete partial response ) treatment irinotecan patient recurrent refractory advance transitional cell carcinoma urothelium previously treat platinum-based chemotherapy . - Determine qualitative quantitative toxic effect drug patient . - Determine overall progression-free survival patient treated drug . OUTLINE : This multicenter study . Patients stratify accord prior pelvic radiotherapy ( yes v ) . Patients receive irinotecan IV 90 minute day 1 . Courses repeat every 21 day absence disease progression unacceptable toxicity . Patients follow every 3 month 1 year every 6 month 2 year . PROJECTED ACCRUAL : A total 20-40 patient accrue study within 5-10 month .</detailed_description>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Transitional Cell</mesh_term>
	<mesh_term>Urethral Neoplasms</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Ureteral Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm transitional cell carcinoma ( TCC ) urothelium , include bladder , renal pelvis , ureter , urethra Stage T24 , N03 , M1 OR stage T24 , N+ , M0 , unresectable disease The following additional histologic subtypes eligible : Poorly differentiate TCC Predominant TCC rare foci squamous differentiation Predominant TCC rare focus adenocarcinoma The following histologic subtypes ineligible : Adenocarcinoma Small cell carcinoma Sarcoma Squamous cell carcinoma Mixed adeno/squamous/transitional histology Incurable surgery radiotherapy Progressed recurred 1 , 1 , prior cisplatin carboplatincontaining systemic regimen metastatic disease Measurable disease Soft tissue disease irradiate within past 2 month consider measurable disease No uncontrolled central nervous system ( CNS ) metastases CNS metastasis respond stabilized prior radiotherapy allow PATIENT CHARACTERISTICS : Age 18 Performance status Zubrod 02 Life expectancy Not specify Hematopoietic Absolute granulocyte count least 1,200/mm^3 Platelet count least 100,000/mm^3 Hepatic Bilirubin less 1.5 time upper limit normal ( ULN ) Aspartate aminotransferase ( SGOT ) less 3 time ULN ( 5 time ULN liver metastasis present ) Renal Creatinine less 2 time ULN Other Not pregnant nursing Fertile patient must use effective contraception No malignancy within past 5 year except adequately treat basal cell squamous cell skin cancer , carcinoma situ cervix , adequately treated stage I II cancer currently complete remission PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy See Disease Characteristics At least 28 day since prior chemotherapy No prior topoisomerase I inhibitor ( e.g. , irinotecan topotecan ) Endocrine therapy Not specify Radiotherapy See Disease Characteristics At least 28 day since prior radiotherapy pelvis Surgery Not specify Other Recovered prior therapy Prior adjuvant therapy allow At least 14 day since prior Hypericum perforatum ( St. John 's Wort ) More 7 day since prior phenytoin , phenobarbital , carbamazepine , enzymeinducing anticonvulsant drug ( EIACDs ) No St. John 's Wort 7 day study participation No concurrent EIACDs No concurrent medication cause myelosuppression No concurrent medication cause diarrhea Concurrent gabapentin nonEIACDs allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>recurrent bladder cancer</keyword>
	<keyword>stage IV bladder cancer</keyword>
	<keyword>metastatic transitional cell cancer renal pelvis ureter</keyword>
	<keyword>recurrent transitional cell cancer renal pelvis ureter</keyword>
	<keyword>regional transitional cell cancer renal pelvis ureter</keyword>
	<keyword>transitional cell carcinoma bladder</keyword>
	<keyword>anterior urethral cancer</keyword>
	<keyword>posterior urethral cancer</keyword>
	<keyword>recurrent urethral cancer</keyword>
	<keyword>urethral cancer associate invasive bladder cancer</keyword>
</DOC>